A study to evaluate the effect of single oral dose of balinatunfib on cardiac repolarization in healthy adult participants.

Trial Identifier:	TES18591
Sponsor:	Sanofi
Start Date:	December 2025
Primary Completion Date:	April 2026
Study Completion Date:	April 2026
Condition:	Healthy Volunteers

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
UNITED STATES, Texas	Dallas, Texas, UNITED STATES, 75247
UNITED STATES, Wisconsin	Madison, Wisconsin, UNITED STATES, 53704

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.